Is Aprea Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: APRE) stock is to Strong Buy APRE stock.
Out of 2 analysts, 1 (50%) are recommending APRE as a Strong Buy, 1 (50%) are recommending APRE as a Buy, 0 (0%) are recommending APRE as a Hold, 0 (0%) are recommending APRE as a Sell, and 0 (0%) are recommending APRE as a Strong Sell.
What is APRE's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: APRE) forecast ROE is N/A, which is considered weak.
What is APRE's Price Target?
According to 2 Wall Street analysts that have issued a 1 year APRE price target, the average APRE price target is $18.00, with the highest APRE stock price forecast at $20.00 and the lowest APRE stock price forecast at $16.00.
On average, Wall Street analysts predict that Aprea Therapeutics's share price could reach $18.00 by May 16, 2024. The average Aprea Therapeutics stock price prediction forecasts a potential upside of 398.61% from the current APRE share price of $3.61.
What is APRE's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: APRE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.